Pre-planned feasibility and safety analyses of docetaxel/S-1 combination in a phase III study comparing docetaxel/S-1 with S-1 alone as postoperative adjuvant chemotherapy for stage III gastric cancer (JACCRO GC-07).

被引：1
|
作者：
Kakeji, Yoshihiro
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Takahashi, Masazumi
Kii, Takayuki
Ishiguro, Atsushi
Ishigure, Kiyoshi
Takagane, Akinori
Matsui, Takanori
Kaji, Masahide
Ichikawa, Wataru
Sano, Takeshi
Takeuchi, Masahiro
Fujii, Masashi
Nakajima, Toshifusa
机构：
[1] Kobe Univ, Grad Sch Med, Dept Surg, Div Gastrointestinal Surg, Kobe, Hyogo 657, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Nagoya, Aichi 4648601, Japan
[3] Gifu Univ, Sch Med, Gifu 500, Japan
[4] Nihon Univ, Sch Med, Tokyo, Japan
[5] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan
[6] Osaka Med Coll Hosp, Ctr Canc Chemotherapy, Osaka, Japan
[7] Teine Keijinkai Hosp, Sapporo, Hokkaido, Japan
[8] Konan Kosei Hosp, Konan, Japan
[9] Hakodate Goryokaku Hosp, Hakodate, Hokkaido, Japan
[10] Aichi Canc Ctr Hosp, Okazaki, Aichi, Japan
[11] Toyama Prefectural Cent Hosp, Toyama, Japan
[12] Showa Univ, Tokyo, Japan
[13] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[14] Kitasato Univ, Tokyo, Japan
[15] Japan Clin Canc Res Org, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15000
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).
    Kodera, Yasuhiro
    Yoshida, Kazuhiro
    Kochi, Mitsugu
    Ichikawa, Wataru
    Kakeji, Yoshihiro
    Sano, Takeshi
    Nagao, Narutoshi
    Takahashi, Masazumi
    Takagane, Akinori
    Nakamura, Masanori
    Kaji, Masahide
    Okitsu, Hiroshi
    Nomura, Takashi
    Matsui, Takanori
    Yoshikawa, Takaki
    Matsuyama, Jin
    Yamada, Makoto
    Ito, Yuichi
    Takeuchi, Masahiro
    Fujii, Masashi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07
    Kakeji, Yoshihiro
    Yoshida, Kazuhiro
    Kodera, Yasuhiro
    Kochi, Mitsugu
    Sano, Takeshi
    Ichikawa, Wataru
    Lee, Sang-Woong
    Shibahara, Kazushige
    Shikano, Toshio
    Kataoka, Masato
    Ishiguro, Atsushi
    Ojima, Hitoshi
    Sakai, Yoshinori
    Musha, Nobuyuki
    Takase, Tsunenobu
    Kimura, Taisei
    Takeuchi, Masahiro
    Fujii, Masashi
    GASTRIC CANCER, 2022, 25 (01) : 188 - 196
  • [3] Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07
    Yoshihiro Kakeji
    Kazuhiro Yoshida
    Yasuhiro Kodera
    Mitsugu Kochi
    Takeshi Sano
    Wataru Ichikawa
    Sang-Woong Lee
    Kazushige Shibahara
    Toshio Shikano
    Masato Kataoka
    Atsushi Ishiguro
    Hitoshi Ojima
    Yoshinori Sakai
    Nobuyuki Musha
    Tsunenobu Takase
    Taisei Kimura
    Masahiro Takeuchi
    Masashi Fujii
    Gastric Cancer, 2022, 25 : 188 - 196
  • [4] Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study)
    Masashi Fujii
    International Journal of Clinical Oncology, 2008, 13
  • [5] Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study)
    Fujii, Masashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (03) : 201 - 205
  • [6] Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
    Noriyuki Hirahara
    Takeshi Matsubara
    Shunsuke Kaji
    Tetsu Yamamoto
    Ryoji Hyakudomi
    Kiyoe Takai
    Kazunari Ishitobi
    Yuki Uchida
    Yoshitsugu Tajima
    BMC Cancer, 21
  • [7] Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
    Hirahara, Noriyuki
    Matsubara, Takeshi
    Kaji, Shunsuke
    Yamamoto, Tetsu
    Hyakudomi, Ryoji
    Takai, Kiyoe
    Ishitobi, Kazunari
    Uchida, Yuki
    Tajima, Yoshitsugu
    BMC CANCER, 2021, 21 (01)
  • [8] Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
    Ishida, Hiroo
    Sunakawa, Yu
    Kodera, Yasuhiro
    Yoshida, Kazuhiro
    Kochi, Mitsugu
    Kakeji, Yoshihiro
    Sano, Takeshi
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 371 - 371
  • [9] Adjuvant Chemotherapy With S-1 Plus Docetaxel Versus S-1 Plus Oxaliplatin in Stage III Gastric Cancer
    Yamamoto, Masaaki
    Omori, Takeshi
    Shinno, Naoki
    Hara, Hisashi
    Mukai, Yosuke
    Sugase, Takahito
    Takeoka, Tomohira
    Mikamori, Manabu
    Kanemura, Takashi
    Hasegawa, Shinichiro
    Akita, Hirofumi
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Wada, Hiroshi
    Matsuda, Chu
    Yasui, Masayoshi
    Miyata, Hiroshi
    Ohue, Masayuki
    ANTICANCER RESEARCH, 2023, 43 (11) : 5015 - 5024
  • [10] Confirmed three-year RFS and OS of the randomized trial of adjuvant S-1 versus S-1 plus docetaxel after curative resection of pStage III gastric cancer (JACCRO GC-07).
    Yoshida, Kazuhiro
    Kodera, Yasuhiro
    Kochi, Mitsugu
    Sano, Takeshi
    Kakeji, Yoshihiro
    Ichikawa, Wataru
    Kurahashi, Shintaro
    Yamaguchi, Hironori
    Toyokawa, Takahiro
    Nakamura, Masato
    Fujitani, Kazumasa
    Mochizuki, Yoshinari
    Ota, Mitsuhiko
    Hihara, Jun
    Makari, Yoichi
    Takeno, Atsushi
    Takeuchi, Masahiro
    Fujii, Masashi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345